David A. Siegel Eye Point Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 33,200 shares of EYPT stock, worth $402,384. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,200
Previous 30,100
10.3%
Holding current value
$402,384
Previous $163,000
91.41%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding EYPT
# of Institutions
160Shares Held
67.1MCall Options Held
214KPut Options Held
994K-
Cormorant Asset Management, LP Boston, MA8.33MShares$101 Million7.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$82.5 Million2.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.8MShares$82.4 Million0.11% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.6MShares$55.7 Million0.09% of portfolio
-
Franklin Resources Inc San Mateo, CA4.3MShares$52.1 Million0.01% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $413M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...